Overview

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
Phase:
PHASE2
Details
Lead Sponsor:
Akeso